BioinfometricsBioinfometrics logo mark — DNA double helix encoded as a financial candlestick chart on an upward trend axis. The dual-read mark simultaneously represents molecular biology and market data intelligence.

Bioinfometrics

The First Huntington’s Gene Therapy Filing Rests on 12 Patients. Its Effect Ranges From 44% to 75% Depending on the Comparison

FDA accepted uniQure’s application for AMT-130 on November 2, with a decision due May 1, 2027. The company’s own slides show the slowing of Huntington’s disease measured against registry patients shrinks from 75% at 36 months to 44% at 48 months when the control group is updated.

Illustration of a small cluster of bright dots on one side of a balance scale, weighed against a large crowd of pale dots, with an amber pointer at the pivot and a dashed second position of the beam
Martin DAVILABy Martin DAVILA11/15/20266

On November 2, uniQure said the FDA had accepted for priority review its Biologics License Application for ifezuntirgene inilparvovec, known as AMT-130, a one-time gene therapy for Huntington's disease injected directly into the brain. The decision date is May 1, 2027, and the agency plans to hold an advisory committee meeting. If approved, it would be the first treatment shown to slow the disease rather than manage its symptoms.

The application rests on an unusual comparison. There is no randomized control group behind the main result. Instead, 12 patients on the high dose, followed for three years, are compared with hundreds of patients drawn from Enroll-HD, a natural history registry. How big the benefit looks depends on that comparison.

What does the filing rest on?

The BLA uses the 36-month analysis from uniQure's Phase I/II studies, with a June 30, 2025 data cut. Seventeen patients received the high dose; 12 had reached 36 months. They were compared with 940 registry patients matched on their characteristics by propensity score, 568 of whom had 36-month data. The primary endpoint is the composite Unified Huntington's Disease Rating Scale (cUHDRS), where a falling score means the disease is getting worse.

In that analysis the high-dose patients lost 0.38 points and the matched registry patients lost 1.52, which uniQure reports as a 75% slowing (p = 0.003). On Total Functional Capacity (TFC), a measure of daily functioning, uniQure reports a 60% slowing (p = 0.033).

What happened at four years?

On September 29, 2026, uniQure presented 48-month data from a June 30, 2026 cut, filed with the SEC. For this analysis the prespecified comparator was an updated release of Enroll-HD, called Enroll-HD B (about 26,000 participants, released September 2025), replacing Enroll-HD A (about 20,000 participants, released January 2023).

The same 12 patients show a 75% slowing at three years and 44% at four, when compared with the updated registry control.

Decline in cUHDRS from baseline, in points (higher means faster worsening). AMT-130 high-dose patients against propensity score-matched Enroll-HD registry patients. 36 mo, A: the BLA analysis against Enroll-HD A. 48 mo, B: the prespecified four-year analysis against Enroll-HD B. 48 mo, A: post hoc analysis against Enroll-HD A.

AMT-130 high doseMatched registry patients

Source: uniQure, AMT-130 program update, Form 8-K exhibit 99.1, September 29, 2026. Slowing is 1 minus treated decline over control decline: 75%, 44% and 54%. P values: 0.003 at 36 months; 0.144 and 0.041 at 48 months, which uniQure labels nominal. Each bar is the least squares mean change reported by uniQure, sign reversed.

View data
analysistreatedcontrol
36 mo, A0.381.52
48 mo, B0.91.61
48 mo, A0.91.94

Against the prespecified Enroll-HD B control, the 48-month slowing on cUHDRS is 44%, with a nominal p value of 0.144, which is not statistically significant. Against the older Enroll-HD A control, in an analysis uniQure labels post hoc, it is 54% (nominal p = 0.041).

TFC held up better. uniQure reports a 61% slowing at 48 months against Enroll-HD B (nominal p = 0.008) and 68% against Enroll-HD A.

Why does the control group matter so much?

Because registry patients drop out, and the ones who stay may not be typical. uniQure's own slides argue that Enroll-HD B "likely understates" disease progression: registry participants followed for longer declined more slowly, missing data reached 53% at month 48, and at four years Enroll-HD B patients declined about 20% less than Enroll-HD A patients (1.65 against 2.05 points).

That may be right. It is also the core weakness of an external control: the comparator is chosen and adjusted after the fact, and a reasonable change of registry release moves the headline by 31 percentage points. In a randomized trial, the control patients would be followed under the same protocol, with the same visits.

Treated patients drop off too. Of the 17 high-dose patients, 12 contribute 36-month data in the BLA analysis and 12 contribute 48-month data.

How did the FDA get here?

The path was not straight. On November 3, 2025, uniQure said that after a pre-BLA meeting it believed the FDA "no longer agrees" that the Phase I/II data compared with an external control could be the primary evidence for approval, a reversal of guidance given in November 2024. On June 17, 2026, after a Type B meeting, the company said the FDA had accepted the three-year analysis as the primary basis for accelerated approval, while asking to align on a confirmatory trial.

That confirmatory trial is now defined: about 200 patients randomized 2:1 to AMT-130 or standard of care, with TFC at 36 months as the primary endpoint. uniQure plans to start screening in the US by the end of 2026. Under accelerated approval, that trial would have to confirm the benefit after the drug is on the market.

Limits

All efficacy numbers here come from uniQure's slides and releases, not from a peer-reviewed paper, and we did not have access to the patient-level data or the matching method. The bars in the chart are least squares means read from the slides; uniQure's "percent slowing" figures are its own, and our recomputation matches them for cUHDRS. The 48-month p values are nominal, meaning not adjusted for multiple analyses. We are not judging whether AMT-130 works; a 44% slowing could be real. We are showing that the size of the effect depends on choices that a randomized trial would not need.

Sources

  1. uniQure, FDA acceptance and priority review of the BLA for ifezuntirgene inilparvovec, Form 8-K exhibit 99.1, November 2, 2026: PDUFA date May 1, 2027, planned advisory committee, 36-month analysis against an Enroll-HD external control, confirmatory trial of about 200 patients, 51 patients dosed, about 75,000 people with Huntington's disease in the US, EU and UK.
  2. uniQure, Phase I/II AMT-130 program update, Form 8-K exhibit 99.1, September 29, 2026: 36-month and 48-month cUHDRS and TFC results, patient counts, Enroll-HD A and B, missingness and survivor bias analyses.
  3. uniQure, Regulatory update on AMT-130, Form 8-K exhibit 99.1, November 3, 2025: FDA feedback at the pre-BLA meeting.
  4. uniQure, Plan for BLA submission for AMT-130, Form 8-K exhibit 99.1, June 17, 2026: FDA acceptance of the three-year analysis as the primary basis for accelerated approval.
  5. ClinicalTrials.gov, NCT04120493 and NCT05243017: the US and European Phase I/II studies.
  6. Related: Half of FDA's new drugs already target rare diseases and optogenetics won the Nobel, but its only trials are in the eye.

Found this article helpful? Share it with your network!

Recommended Reading

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!